A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab
- Indications Bladder cancer; Malignant melanoma
- Focus Therapeutic Use
- 09 Feb 2018 Planned End Date changed from 1 Sep 2018 to 1 Sep 2019.
- 09 Feb 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
- 10 Jun 2017 Biomarkers information updated